StockData
Lakefront Biotherapeutics NV logo

Lakefront Biotherapeutics NV (LKFT) stock

LKFTNasdaqPharmaceutical PreparationsAlso trades as GLPGF
Financials through fiscal 2025, year ended Dec 31, 2025Score 7/30
$34.39−0.40 (-1.15%)

Close on Nov 17, 2026Market cap $2.27BP/E 6.4Yield –

Lakefront Biotherapeutics cash

Cash and short-term investments held at the end of each period.

Lakefront Biotherapeutics's cash was €87.87M at Dec 31, 2025. For fiscal 2025 it was €87.87M, up 36.8% from the year before. Over ten years it grew -12.7% a year on average. The highest annual figure on record is €2.23B in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025€87.87M+36.8%
FY2024Dec 31, 2024€64.24M-61.5%
FY2023Dec 31, 2023€166.80M-67.2%
FY2022Dec 31, 2022€508.12M-77.2%
FY2021Dec 31, 2021€2.23B+4.6%
FY2020Dec 31, 2020€2.14B+14.7%
FY2019Dec 31, 2019€1.86B+44.2%
FY2018Dec 31, 2018€1.29B+12.1%
FY2017Dec 31, 2017€1.15B+18.3%
FY2016Dec 31, 2016€973.24M+186.0%
FY2015Dec 31, 2015€340.31M+81.3%
FY2014Dec 31, 2014€187.71M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025€87.87M-96.1%
Q4 FY2024Dec 31, 2024€64.24M-97.6%
Q4 FY2023Dec 31, 2023€166.80M-92.2%
Q4 FY2022Dec 31, 2022€508.12M-78.7%
Q4 FY2021Dec 31, 2021€2.23B+20.0%
Q2 FY2021Jun 30, 2021€2.64B+130.2%
Q4 FY2020Dec 31, 2020€2.14B+65.4%
Q2 FY2020Jun 30, 2020€2.38B+123.5%
Q4 FY2019Dec 31, 2019€1.86B+61.7%
Q2 FY2019Jun 30, 2019€1.15B-9.0%
Q4 FY2018Dec 31, 2018€1.29B+32.6%
Q2 FY2018Jun 30, 2018€1.07B+213.5%
Q4 FY2017Dec 31, 2017€1.15B+513.3%
Q2 FY2017Jun 30, 2017€1.26B–
Q4 FY2016Dec 31, 2016€973.24M–
Q4 FY2015Dec 31, 2015€340.31M–
Q4 FY2014Dec 31, 2014€187.71M–

More Lakefront Biotherapeutics figures

See a number that looks wrong?